Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (143)

Fever (23)

Cough (18)

Respiratory distress (15)

Dyspnea (9)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 146
    records per page




    Clinical characteristics of neonates with coronavirus disease MESHD 2019 (COVID-19): a systematic review

    Authors: Yuan Hu; Jing Xiong; Yuan Shi

    doi:10.21203/rs.3.rs-50795/v1 Date: 2020-07-29 Source: ResearchSquare

    This study aimed to summarize the existing literature on severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection in newborns to clarify the clinical features and outcomes of neonates with COVID-19. A systematic search was performed in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP databases from January 1, 2019 to April 30, 2020. The references of relevant studies were also searched. A descriptive summary was organized by aspects of clinical presentations (symptoms, laboratory examinations, and imaging) and outcomes. We identified 14 studies reporting 18 newborns with COVID-19. The most common clinical manifestations were fever MESHD fever HP (62.5%), shortness of breath (50.0%), diarrhea MESHD diarrhea HP/ vomiting MESHD vomiting HP/feeding intolerance(43.8%), cough MESHD cough HP (37.5%), dyspnea MESHD dyspnea HP (25.0%), and nasal congestion/runny nose/ sneeze MESHD sneeze HP(25.0%). Atypical symptoms included jaundice MESHD jaundice HP and convulsion. Lymphocyte numbers decreased in 5 cases, and radiographic findings were likely to show pneumonia MESHD pneumonia HP. All newborns recovered and discharged from the hospital, and there was no death MESHD.Conclusion: Clinical symptoms of neonatal SARS-CoV-2 infection MESHD are atypical, most of them are mild. Up to now, the prognosis of newborns is good, and there is no death MESHD. Intrauterine vertical transmission TRANS is possible, but confirmed evidence is still lacking. The Long-term follow-up of potential influences of SARS-CoV-2 infection MESHD on neonates need further exploration.

    Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia MESHD pneumonia HP treated with high-titer convalescent plasma SERO: a prospective study

    Authors: Michele Donato; Steven Park; Melissa Baker; Robert Korngold; Alison Morawski; Xue Geng; Ming Tony Tan; Scott Rowley; Kar Chow; Emily Brown; Joshua Zenreich; Phyllis McKiernan; Kathryn Buttner; Anna Ullrich; Laura Long; Marlo Kemp; Mariefel Vendivil; Andrea Ricourt; Rena Feinman; Hyung Suh; Balani Bindu; Cristina Cicogna; Rani Sebti; Abdulla Al-Khan; Steven Sperber; Samit Desai; Stacey Fanning; Danit Arad; Ronaldo Go; Elizabeth Tam; Keith Rose; Sean Sadikot; David S Siegel; Martin Gutierrez; Andrew Ip; Stuart Goldberg; Tatyana Feldman; Andre Goy; Andrew Pecora; Noa Biran; Lori Leslie; Alfred Gillio; Sarah Timmapuri; Michele Boonstra; Samuel Singer; Sukhdeep Kaur; Ernest Richards; David Perlin

    doi:10.1101/2020.07.20.20156398 Date: 2020-07-26 Source: medRxiv

    Background Effective antiviral therapy against the severe acute respiratory syndrome MESHD virus 2 (SARS-CoV-2) remains elusive. Convalescent plasma SERO is an anti-viral approach currently under investigation. We aimed to assess the laboratory and clinical parameters of patients with COVID-19 pneumonia MESHD pneumonia HP treated with convalescent plasma SERO containing high levels of neutralizing anti- SARS-CoV-2 antibodies SERO.

    Point mutation bias in SARS-CoV-2 variants results in increased ability to stimulate inflammatory responses

    Authors: Masato Kosuge; Emi Furusawa-Nishii; Koyu Ito; Yoshiro Saito; Kouetsu Ogasawara

    doi:10.21203/rs.3.rs-48745/v1 Date: 2020-07-25 Source: ResearchSquare

    Severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD induces severe pneumonia MESHD pneumonia HP and is the cause of a worldwide pandemic. Coronaviruses, including SARS-CoV-2, have RNA proofreading enzymes in their genomes, resulting in fewer gene mutations than other RNA viruses. Nevertheless, variants of SARS-CoV-2 exist and may induce different symptoms; however, the factors and the impacts of these mutations are not well understood. We found that there is a bias to the mutations occurring in SARS-CoV-2 variants, with disproportionate mutation to uracil (U). These point mutations to U are mainly derived from cytosine (C), which is consistent with the substrate specificity of host RNA editing enzymes, APOBECs. We also found the point mutations which are consistent with other RNA editing enzymes, ADARs. For the C-to-U mutations, the context of the upstream uracil and downstream guanine from mutated position was found to be most prevalent. Further, the degree of increase of U in SARS-CoV-2 variants correlates with enhanced production of cytokines, such as TNF-a and IL-6, in cell lines when compared with stimulation by the ssRNA sequence of the isolated virus in Wuhan. Therefore, RNA editing is a factor for mutation bias in SARS-CoV-2 variants, which affects host inflammatory cytokines production.

    Starting from the Influence of Tobacco: AKR1C3 and COVID-19 Receptor ACE2 Are Potential Pprognostic Biomarkers for Brain Lower Grade Glioma MESHD Glioma HP, Evidence from Bioinformatics Analyses

    Authors: Heng-Yi Yang; Tian-Ni Mao

    id:10.20944/preprints202007.0411.v1 Date: 2020-07-19 Source: Preprints.org

    Background: Coronavirus disease MESHD (COVID-19) related pneumonia MESHD pneumonia HP is leaded by Severe Acute Respiratory Syndrome MESHD Coronavirus 2 (SARS-CoV-2), which infects host cells through receptors named Angiotensin-converting enzyme 2 (ACE2). Smoking is thought to be related to poor disease MESHD prognosis, as a large amount of evidence highlights the negative effects of smoking on lung health and its causal relationship with various respiratory diseases MESHD. Methods: We first evaluated the role of ACE2 expression level with tobacco effect. And correlation analyses were used to identify the related genes of ACE2 both in smoker trait and human normal multi-tissues. After intersections, hub genes were later used to further GSEA and co-regulated mechanisms were explored by GeneMANIA. We used UALCAN to perform survival curves of pan-cancers included 33 types of cancers. New clinical model of top co-occurrence cancer type was constructed and validated. Results: Effected by cigarette smoking, the expression level of ACE2 expressed statistically upwards in current smokers compared with never smokers, upwards in groups after acute smoke exposed compared with normal control. But no strong evidence detected in third-hand smoke, as poor amounts of samples, only 4. A little trend of expressing upwards became in groups after third-hand smoke compared with groups after clean air exposing. 4 genes included PIR, ADH7, AKR1C2 and AKR1C3 were identified as ACE2 related genes in smoker trait and human normal multi-tissues. Then, we made the survival curves of pan-cancers in 4 genes. Brain lower grade glioma MESHD glioma HP was the co-occurrence type as both ACE2, PIR and AKR1C3 had the significantly prognostic situation. Later, we made the new clinical prediction model as the C-index was 0.827 and the Area Under Curves (AUCs) of 1-year survival, 2-year survival and 3-year survival were 0.921(95%CI, 0.882-0.961), 0.911(95%CI, 0.860-0.962) and 0.878(95%CI, 0.818-0.939). In inner validation, the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.777(95%CI, 0.640-0.914), 0.916(95%CI, 0.842-0.990) and 0.888(95%CI, 0.768-1.000). In outer validation one, the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.764(95%CI, 0.672-0.856), 0.848(95%CI, 0.783-0.913) and 0.748(95%CI, 0.656-0.841). And in outer validation two the AUCs of 1-year survival, 2-year survival and 3-year survival were 0.740(95%CI, 0.654-0.826), 0.766(95%CI, 0.688-0.843) and 0.794(95%CI, 0.721-0.866). Conclusions: In our study, we compared the ACE2 expression level between smokers and non-smokers crowds and identified associated hub genes. Then we explored the further role of hub genes in tumor fields to identify the correlation and influence between the avoidable host factors such as smoking on COVID-19 contamination and tumor. ACE2 and AKR1C3 are potential prognostic genes for brain lower grade glioma MESHD glioma HP, and we created the web dynamic nomogram and encapsulation app through validations.

    New SARS-CoV-2 Infection MESHD in a Pet Cat with Severe Lung Disease MESHD in Italy

    Authors: Nicolò Musso; Angelita Costantino; Sebastiano La Spina; Alessandra Finocchiaro; Francesca Andronico; Stefano Stracquadanio; Luigi Liotta; Rosanna Visalli; Giovanni Emmanuele

    id:10.20944/preprints202007.0398.v1 Date: 2020-07-17 Source: Preprints.org

    The pandemic respiratory disease MESHD COVID-19, caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and then spread throughout the world; Italy was the most affected European country. Despite the close pet-human contact, little is known about the predisposition of pets to SARS-CoV-2. Among these, felines are the most susceptible. In this study, a domestic cat with clear symptoms of pneumonia MESHD pneumonia HP, confirmed by Rx imaging, was found to be infected by SARS-CoV-2 using quantitative RT–qPCR from a nasal swab. This is the first Italian study reporting on the request of the scientific community to focus attention on the possible role of pets as a SARS-CoV-2 reservoir. An important question remains unanswered: did the cat die from SARS-CoV-2 infection MESHD?

    Risk factors for illness severity in patients with COVID-19 pneumonia MESHD pneumonia HP: a prospective cohort study

    Authors: Nannan Zhang; Hairong Zhang; Yanhua Tang; Hao Zhang; Aiying Ma; Fang Xu; Yu Sun; Fangzhen Shan; Luning Jiang

    doi:10.21203/rs.3.rs-44223/v1 Date: 2020-07-16 Source: ResearchSquare

    Background Although COVID-19 pneumonia MESHD pneumonia HP is spreading internationally, knowledge regarding the factors associated with the illness severity of patients remains limited. We aimed to identify the factors associated with the disease MESHD severity of patients with COVID-19 pneumonia MESHD pneumonia HP induced by a novel coronavirus, severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). Methods We prospectively enrolled a single-center case series of adult TRANS patients with COVID-19 admitted to the Infectious Disease MESHD Hospital of Jining, Jining City, Shandong Province, China, from January 24 to March 1, 2020. Demographics, clinical characteristics, and laboratory findings were compared to investigate the risk factors related with the disease MESHD severity of COVID-19 pneumonia MESHD pneumonia HP patients. Results We included a total of 78 patients with COVID-19 pneumonia MESHD pneumonia HP, of whom 6 had the severe type. As compared to a moderately ill cohort, our analysis showed that shortness of breath, fatigue MESHD fatigue HP, neutrophil percentages > 70%, neutrophil counts > 6.3 × 10 9 /L, lymphocyte percentages < 20%, lymphocyte counts < 1.0 × 10 9 /L, platelet < 100 × 10 9 /L, C-reactive protein (CRP) > 10 mg/L, neutrophil to platelet ratio (NPR) > 2.3, neutrophil to lymphocyte ratio (NLR) > 3.9, aspartate aminotransferase (AST) > 40 U/L, albumin < 40 g/L, lactate dehydrogenase (LDH) > 245 U/L, and glucose > 6.1 mmol/L were predictors of disease MESHD severity in COVID-19 pneumonia MESHD pneumonia HP. In the sex-, age TRANS-, and comorbid illness-matched case-control study, neutrophil percentages > 70%, neutrophil counts > 6.3 × 10 9 /L, lymphocyte percentages < 20%, NPR > 2.3, NLR > 3.9, albumin < 40 g/L, and LDH > 245 U/L remained associated with the early detection and identification of severe patients. Conclusion We demonstrated that neutrophil percentages > 70%, neutrophil counts > 6.3×10 9 /L, lymphocyte percentages < 20%, NPR > 2.3, NLR > 3.9, albumin < 40 g/L, and LDH > 245 U/L might predict the severity of illness in patients with COVID-19 pneumonia MESHD pneumonia HP.

    COVID-19 scenarios for the United States

    Authors: - I IHME COVID-19 Forecasting Team; Simon I Hay

    doi:10.1101/2020.07.12.20151191 Date: 2020-07-14 Source: medRxiv

    The United States (US) has not been spared in the ongoing pandemic of novel coronavirus disease MESHD. COVID-19, caused by the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), continues to cause death MESHD and disease MESHD in all 50 states, as well as significant economic damage wrought by the non-pharmaceutical interventions (NPI) adopted in attempts to control transmission TRANS. We use a deterministic, Susceptible, Exposed, Infectious, Recovered (SEIR) compartmental framework to model possible trajectories of SARS-CoV-2 infections MESHD and the impact of NPI at the state level. Model performance SERO was tested against reported deaths MESHD from 01 February to 04 July 2020. Using this SEIR model and projections of critical driving covariates ( pneumonia MESHD pneumonia HP seasonality, mobility, testing rates, and mask use per capita), we assessed some possible futures of the COVID-19 pandemic from 05 July through 31 December 2020. We explored future scenarios that included feasible assumptions about NPIs including social distancing mandates (SDMs) and levels of mask use. The range of infection MESHD, death MESHD, and hospital demand outcomes revealed by these scenarios show that action taken during the summer of 2020 will have profound public health impacts through to the year end. Encouragingly, we find that an emphasis on universal mask use may be sufficient to ameliorate the worst effects of epidemic resurgences in many states. Masks may save as many as 102,795 (55,898-183,374) lives, when compared to a plausible reference scenario in December. In addition, widespread mask use may markedly reduce the need for more socially and economically deleterious SDMs.

    Predictability of Blood SERO Parameters on the Course of Covid-19- a retrospective clinical study

    Authors: Ahmet Rıfkı Çora; Ersin Çelik

    doi:10.21203/rs.3.rs-42362/v1 Date: 2020-07-13 Source: ResearchSquare

    Background In December 2019, clusters of patients with pneumonia MESHD pneumonia HP of an unkown cause were reported in Wuhan, Hubei Province in China. On january 2020, Chinese scientists identified this as a novel coronavirus, temporarily labelled as, severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2). Although recent studies investigating predictors of poor prognosis at an early stage identified exact parameters as a predictor for the disease MESHD still controversial. Here we study biochemical and hematologic parameters of 197 patients diagnosed as Covid-19 at our hospital for evaluating the value of these biomarkers for predicting the course of Covid-19 disease MESHD.Material and Method197 patients who were diagnosed with Covid-19 at our hospital according to World Health Organisation (WHO) interim guidance were screened between march 2020-may 2020 retrospectiveley for the study. Patients selected from the population of service and intensive care unit (ICU). Biochemical and hematologic parameters retrospectively evaluated for predicting the course of Covid-19 disease MESHD.ResultsAmong 197 patient population of service and ICU, hematological and biochemical parameters studied. There was a significiant association found between the parameters neurtophile/lymphocyet ratio, white blood SERO cell, eosynophile, monocyte, lymphocyte counts and high sensitive troponin-I levels and ICU admission.   ConclusionWe found increased levels of neutrophile/lymphocyte ratio, white blood SERO cell count and high sensitive troponin-I and decreased levels of eosynophile, monocyte and lymphocyte counts among ICU admitted patients. We concluded that these biochemical and hematologic parameters can be used for the predicting the course of Covid-19 disease MESHD.

    RNA-Dependent RNA Polymerase and Spike Protein Mutant Variants of SARS-CoV-2 Predominate in Severely Affected COVID-19 Patients

    Authors: Subrata K. Biswas; Sonchita R. Mudi

    id:10.20944/preprints202007.0251.v1 Date: 2020-07-12 Source: Preprints.org

    The severity of coronavirus disease MESHD 2019 (COVID-19), caused by the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), greatly varies from patient to patient. In the present study, we explored and compared mutation profiles of SARS-CoV-2 isolated from mildly affected and severely affected COVID-19 patients in order to explore any relationship between mutation profile and disease MESHD severity. Genomic sequences of SARS-CoV-2 were downloaded from GISAID database. With the help of Genome Detective Coronavirus Typing Tool, genomic sequences were aligned with the Wuhan seafood market pneumonia MESHD pneumonia HP virus reference sequence and all the mutations were identified. Distribution of mutant variants was then compared between mildly and severely affected groups. Among the numerous mutations detected, 14,408C>T and 23,403A>G mutations resulting in RNA-dependent RNA polymerase (RdRp) P323L and spike protein D614G mutations, respectively, were found predominantly in severely affected group (>82%) compared with mildly affected group (<46%, p<0.001). The 241C>T mutation in the non-coding region of the genome was also found predominantly in severely affected group. The 3,037C>T, a silent mutation, also appeared in relatively high frequency in severely affected group. We concluded that RdRp P323L and spike protein D614G mutations predominate in severely affected COVID-19 patients. Further studies will be required to explore whether these mutations have any impact on the severity of COVID-19.

    SARS-CoV-2 infection MESHD in the lungs of human ACE2 transgenic mice causes severe inflammation MESHD, immune cell infiltration, and compromised respiratory function

    Authors: Emma S Winkler; Adam L Bailey; Natasha M Kafai; Sharmila Nair; Broc T McCune; Jinsheng Yu; Julie M Fox; Rita E Chen; James T Earnest; Shamus P Keeler; Jon H Ritter; Liang-I Kang; Sarah Dort; Annette Robichaud; Richard Head; Michael J Holtzman; Michael S Diamond

    doi:10.1101/2020.07.09.196188 Date: 2020-07-10 Source: bioRxiv

    Severe Acute Respiratory Syndrome MESHD Coronavirus -2 (SARS-CoV-2) emerged in late 2019 and has spread worldwide resulting in the Coronavirus Disease MESHD 2019 (COVID-19) pandemic. Although animal models have been evaluated for SARS-CoV-2 infection MESHD, none have recapitulated the severe lung disease MESHD phenotypes seen in hospitalized human cases. Here, we evaluate heterozygous transgenic mice expressing the human ACE2 receptor driven by the epithelial cell cytokeratin-18 gene promoter (K18-hACE2) as a model of SARS-CoV-2 infection MESHD. Intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice results in high levels of viral infection MESHD in lung tissues with additional spread to other organs. Remarkably, a decline in pulmonary function, as measured by static and dynamic tests of respiratory capacity, occurs 4 days after peak viral titer and correlates with an inflammatory response marked by infiltration into the lung of monocytes, neutrophils, and activated T cells resulting in pneumonia MESHD pneumonia HP. Cytokine profiling and RNA sequencing analysis of SARS-CoV-2-infected lung tissues show a massively upregulated innate immune response with prominent signatures of NF-kB-dependent, type I and II interferon signaling, and leukocyte activation pathways. Thus, the K18-hACE2 model of SARS-CoV-2 infection MESHD recapitulates many features of severe COVID-19 infection MESHD in humans and can be used to define the mechanistic basis of lung disease MESHD and test immune and antiviral-based countermeasures.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.